The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

New eczema drug from Eli Lilly receives FDA approval for children and adults Reuters On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21) and CCB (HR, 1.16); the smallest effect sizes were for ACE ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

More than 31.6 million Americans have eczema (also called atopic dermatitis). Half of them say they're frustrated by this itchy skin condition. Creams can help relieve the itch, and steroids bring ...

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The ...